Incidence of Inhibitors in Previously Untreated Patients with Severe Hemophilia a Treated with Plasma-Derived Vs. Recombinant Factor VIII Concentrates: A Systematic Review and Meta-Analyses

被引：0
|
作者：
Prezotti, Alessandra N. L. [1 ,2 ]
Villaca, Paula Ribeiro [3 ]
Rocha, Debora M. C. [2 ]
Orletti, Maria P. S. V. [2 ]
Lourenco, Christiane [2 ]
Yamaguti Hayakawa, Gabriela G. [1 ,4 ]
Ozelo, Margareth C. [1 ,4 ]
机构：
[1] Univ Estadual Campinas, Sch Med Sci, Dept Internal Med, UNICAMP, Campinas, SP, Brazil
[2] HEMOES, Hemoctr Espirito Santo, Vitoria, ES, Brazil
[3] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, SP, Brazil
[4] Univ Estadual Campinas, Hemoctr UNICAMP, Campinas, SP, Brazil
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-171028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Inhibitor incidence in previously untreated patients (PUPs) with severe hemophilia A receiving recombinant factor (rFVIII)
    Rothschild, C
    Laurian, Y
    Satre, EP
    BorelDerlon, A
    Chambost, H
    Moreau, P
    Goudemand, J
    Parquet, A
    Vicariot, M
    Beurrier, P
    Claeyssens, S
    Durin, A
    Faradji, A
    Fressinaud, E
    Gaillard, S
    Guerin, V
    Guerois, C
    Pernod, G
    Peynet, J
    Pouzol, P
    Schved, JF
    Gazengel, C
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2654 - P2654
  • [42] ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES
    O'Day, K.
    Runken, M. C.
    Meyer, K. L.
    Spears, J. B.
    VALUE IN HEALTH, 2017, 20 (05) : A216 - A217
  • [43] Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review
    Iorio, A.
    Halimeh, S.
    Bidlingmaier, C.
    Ettingshausen, C. E.
    Gringeri, A.
    Holzhauer, S.
    Knoefler, R.
    Kreuz, W.
    Kurnik, K.
    Manner, D.
    Santagostino, E.
    Mannucci, P. M.
    Nowak-Goettl, U.
    HAEMOPHILIA, 2010, 16 (02) : 410 - 410
  • [44] Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A
    Steele, M. R.
    Nagel, K.
    Chan, A. K. C.
    HAEMOPHILIA, 2014, 20 (01) : E100 - E101
  • [45] Multicenter comparison of inhibitor (Inh) development on plasma-derived (PD) vs recombinant (rec) factor VIII(fVIII) in severe hemophilia a patients (sHA pts).
    DiMichele, D
    Rothschild, C
    Sultan, Y
    Kroner, B
    Aledort, L
    BLOOD, 1999, 94 (10) : 238A - 238A
  • [46] Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates
    Dingli, D
    Gastineau, DA
    Gilchrist, GS
    Nichols, WL
    Wilke, JL
    HAEMOPHILIA, 2002, 8 (05) : 629 - 634
  • [47] RECOMBINANT FACTOR-VIII FOR THE TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA-A - SAFETY, EFFICACY, AND DEVELOPMENT OF INHIBITORS
    LUSHER, JM
    ARKIN, S
    ABILDGAARD, CF
    SCHWARTZ, RS
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (07): : 453 - 459
  • [48] CLINICAL-STUDIES OF RECOMBINANT FACTOR-VIII (RECOMBINATE) IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA-A
    BRAY, GL
    LEE, ML
    COURTER, S
    GOMPERTS, E
    BLOOD, 1993, 82 (10) : A446 - A446
  • [49] INCIDENCE OF FACTOR-VIII INHIBITOR DEVELOPMENT IN SEVERE HEMOPHILIA-A PATIENTS TREATED ONLY WITH ONE BRAND OF HIGHLY PURIFIED PLASMA-DERIVED CONCENTRATE
    GUEROIS, C
    LAURIAN, Y
    ROTHSCHILD, C
    PARQUETGERNEZ, A
    DUCLOS, AM
    NEGRIER, C
    VICARIOT, M
    FIMBEL, B
    FRESSINAUD, E
    FIKSSIGAUD, M
    DERLON, A
    BERTHIER, AM
    GAILLARD, S
    BERTRAND, MA
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (02) : 215 - 218
  • [50] Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al.
    Farrugia, Albert
    Bansal, Megha
    BLOOD TRANSFUSION, 2019, 17 (01) : 85 - 85
12345